CNS Pharmaceuticals, Inc.
CNSP
$5.52
-$0.60-9.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 65.76% | -23.65% | -11.99% | -1.76% | 53.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.07% | -42.20% | -4.70% | 22.36% | -40.51% |
| Operating Income | -87.07% | 42.20% | 4.70% | -22.36% | 40.51% |
| Income Before Tax | -87.50% | 42.59% | 6.16% | -21.34% | 40.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -87.50% | 42.59% | 6.16% | -21.34% | 40.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.50% | 42.59% | 6.16% | -21.34% | 40.91% |
| EBIT | -87.07% | 42.20% | 4.70% | -22.36% | 40.51% |
| EBITDA | -87.09% | 42.21% | 4.71% | -22.36% | 40.52% |
| EPS Basic | 72.66% | 96.24% | -- | -- | -- |
| Normalized Basic EPS | 72.65% | 96.24% | -- | -- | -- |
| EPS Diluted | 72.66% | 96.24% | -- | -- | -- |
| Normalized Diluted EPS | 72.65% | 96.24% | -- | -- | -- |
| Average Basic Shares Outstanding | 585.81% | 1,427.05% | -- | -- | -- |
| Average Diluted Shares Outstanding | 585.81% | 1,427.05% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |